<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2502256932
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Acumig
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LASMIDITAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        321.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Acumig is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults.</p><ul><li>Acumig is not used as a preventive treatment of migraine.</li><li>It is not known if lasmiditan is safe and effective in children.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Before you take Acumig, tell your healthcare provider about all of your medical conditions, including if you: </strong></p><ul><li>Have liver problems</li><li>Have high blood pressure</li><li>Have a low heart rate</li><li>Are allergic to lasmiditan</li><li>Are pregnant or plan to become pregnant. It is not known if lasmiditan will harm your unborn baby.</li><li>&nbsp;Are breastfeeding or plan to breastfeed. It is not known if lasmiditan passes into your breastmilk.<strong>&nbsp;</strong></li></ul><p><strong>Warnings and precautions</strong><br /><em>What should I avoid while taking Acumig? </em></p><ul><li>Do not drive or operate machinery for at least 8 hours after taking Acumig.</li><li>You should not drink alcohol or take other medicines that make you drowsy while taking Acumig.</li></ul><p><strong>Other medicines and Acumig</strong><br />Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider will decide if you can take Acumig with your other medicines.</p><p><strong>&nbsp;</strong><em>Especially, tell your healthcare provider if you take: </em></p><ul><li>Propranolol or other medicines that can lower your heart rate</li><li>Any medicines that can increase your blood pressure</li><li>Any medicines that make you sleepy</li><li>Anti-depressant medicines called:<ul><li>Selective serotonin reuptake inhibitors (SSRIs)</li><li>Serotonin norepinephrine reuptake inhibitors (SNRIs)</li><li>Tricyclic anti-depressants (TCAs)</li><li>Monoamine oxidase inhibitors (MAOIs)</li></ul></li></ul><p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them and show it to your healthcare provider or pharmacist when you get a new medicine<strong>.</strong></p><p><strong>Driving and using machines</strong></p><ul><li>Do not drive or operate machinery for at least 8 hours after you take Acumig, even if you feel well enough.</li><li>You should not take Acumig if you cannot wait at least 8 hours between taking Acumig and driving or operating machinery.</li></ul><p><strong>Acumig with alcohol</strong></p><ul><li>You should not drink alcohol or take other medicines that make you drowsy while taking Acumig.</li></ul><p><strong>Acumig contains sodium</strong><br />Acumig contains sodium. Each film-coated tablet of Acumig 50 mg and 100 mg Film-coated Tablets contains 0.468 mg or 0.936 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Take Acumig exactly as your healthcare provider tells you to take it.</li><li>The recommended dose is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours, and Acumig should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery.</li><li>A second dose of lasmiditan has not been shown to be effective for the same migraine attack.</li><li>Your healthcare provider may change your dose. Do not change your dose without first talking to your healthcare provider.</li><li>Take Acumig tablets by mouth with or without food.</li><li>Swallow Acumig tablets whole. Do not split, crush, or chew.</li></ul><p><strong>If you take more </strong><strong>Acumig</strong><strong> than you should</strong></p><ul><li>Do not take more than one dose in a 24-hour period.</li><li>If you take lasmiditan 50 mg, 100 mg, or 200 mg, and your headache goes away but comes back, you should not take a second dose within 24 hours.</li><li>Some people who take too many Acumig tablets may have worse headaches (medication overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with Acumig.</li><li>You should write down when you have headaches and when you take Acumig so you can talk to your healthcare provider about how Acumig is working for you.</li></ul><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Lasmiditan</em></strong><strong> <em>can cause serious side effects including:</em></strong><br /><strong>See &ldquo;What is the most important information I should know about lasmiditan?&rdquo;</strong></p><ul><li>Serotonin syndrome. Serotonin syndrome is a rare but serious problem that can happen in people using lasmiditan, especially if lasmiditan is used with anti-depressant medicines called SSRIs or SNRIs. Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome:<ul><li>Mental changes such as seeing things that are not there (hallucinations), agitation, or coma</li><li>Fast heartbeat</li><li>Changes in blood pressure</li><li>High body temperature</li><li>Tight muscles</li><li>Trouble walking</li><li>Nausea, vomiting, or diarrhea</li></ul></li><li>Medication overuse headache. Some people who take medicines like lasmiditan for the acute treatment of migraine attacks for 10 or more days each month may have worse headaches (medication overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with lasmiditan.</li></ul><p><strong>The most common side effects of lasmiditan include: </strong></p><ul><li>Dizziness</li><li>Numbness</li><li>Tingling</li><li>Sleepiness</li><li>Feeling tired</li></ul><p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of lasmiditan. For more information ask your healthcare provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. &nbsp;The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lasmiditan hemi succinate.</p><p>Each film-coated tablet of Acumig 50 mg Film-coated Tablets contains 57.825 mg lasmiditan hemi succinate equivalents to 50 mg lasmiditan.</p><p>Each film-coated tablet of Acumig 100 mg Film-coated Tablets contains 115.65 mg lasmiditan hemi succinate equivalents to 100 mg lasmiditan.</p><p>The other ingredients are microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, sodium lauryl sulfate, Syloid, magnesium stearate, Opadry gray (only in Acumig 50 mg Film-coated Tablets) and Opadry purple (only in Acumig 100 mg Film-coated Tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Acumig 50 mg Film-coated Tablets are light gray-colored oval film-coated tablets, debossed with “LH” on one side and “1” on the other side in aluminum-aluminum blisters. 

Acumig 100 mg Film-coated Tablets are light purple-colored oval film-coated tablets, debossed with “LH” on one side and “2” on the other side in aluminum-aluminum blisters. 

Pack sizes: 4 and/or 8 Film-coated Tablets.

Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section<br />P.O. Box: 1853<br />Tel: 80011111<br />Email: pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2023; version number Un1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اكيومج هو دواء يصرف بوصفة طبية يستخدم لعلاج نوبات الصداع النصفي الحادة المصحوبة بأورة أو من دونها عند البالغين.</p><ul dir="rtl"><li>لا يستخدم اكيومج كعلاج وقائي للصداع النصفي.</li><li>ليس معروفاً إذا ما كان لاسميديتان آمناً وفعّالاً في الأطفال.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قبل تناول اكيومج، أخبر مقدم الرعاية الصحية الخاص بك عن جميع الحالات الطبية التي تعاني منها، بما في ذلك إذا كنت: </strong></p><ul dir="rtl"><li>تعاني من مشاكل في الكبد</li><li>تعاني من ارتفاع ضغط الدم</li><li>لديك معدل ضربات قلب منخفض</li><li>لديك حساسية من لاسميديتان</li><li>حاملاً أو تخططين لذلك. من غير المعروف إذا ما كان سيضر لاسميديتان جنينك.</li><li>تُرضعين رضاعة طبيعية أو تخططين لذلك. من غير المعروف إذا ما كان لاسميديتان ينتقل إلى حليب الثدي.</li></ul><p><strong>&nbsp;الاحتياطات والتحذيرات&nbsp;</strong><br /><em>ما الذي يجب علي تجنبه أثناء تناول اكيومج؟ </em></p><ul dir="rtl"><li>لا تقم بالقيادة أو تشغيل الآلات لمدة 8 ساعات على الأقل بعد تناول اكيومج.</li><li>يجب ألا تشرب الكحول أو تتناول أدوية أخرى تجعلك تشعر بالنعاس أثناء تناولك اكيومج.</li></ul><p><strong>الأدوية الأخرى واكيومج&nbsp;</strong><br />أخبر مقدم الرعاية الصحية الخاص بك عن جميع الأدوية التي تتناولها بما في ذلك الأدوية التي يتم صرفها بوصفة طبية وبدون وصفة طبية، الفيتامينات، والمكملات العشبية. سيقرر مقدم الرعاية الصحية الخاص بك إذا كان بإمكانك تناول اكيومج مع أدويتك الأخرى.</p><p><strong>&nbsp;</strong><em>أخبر مقدم الرعاية الصحية وخاصة إذا كنت تتناول: </em></p><ul dir="rtl"><li>بروبرانولول أو أدوية أخرى يمكن أن تخفض معدل ضربات القلب</li><li>أي أدوية يمكن أن تزيد من ضغط الدم لديك</li><li>أي أدوية تجعلك تشعر بالنعاس</li><li>الأدوية المضادة للاكتئاب التي تسمى:<ul><li>مثبطات استرداد السيروتونين الانتقائية</li><li>مثبطات استرداد السيروتونين والنورأدرينالين</li><li>مضادات الاكتئاب ثلاثية الحلقات</li><li>مثبطات أكسيداز أحادي الأمين</li></ul></li></ul><p dir="RTL">اسأل مقدم الرعاية الصحية الخاص بك أو الصيدلي عن قائمة هذه الأدوية إذا لم تكن متأكداً. كن على علم بالأدوية التي تتناولها. واحتفظ بقائمة منها واعرضها على مقدم الرعاية الصحية الخاص بك أو الصيدلي عند حصولك على دواء جديد<strong>.</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><ul dir="rtl"><li>لا تقم بالقيادة أو تشغل الآلات لمدة 8 ساعات على الأقل بعد تناول اكيومج، حتى لو شعرت بأنك في حالة جيدة.</li><li>يجب ألا تتناول اكيومج إذا كنت لا تستطيع الانتظار لمدة 8 ساعات على الأقل بين تناول اكيومج والقيادة أو تشغيل الآلات.</li></ul><p><strong>اكيومج مع الكحول</strong></p><ul><li>يجب ألا تشرب الكحول أو تتناول أدوية أخرى تجعلك تشعر بالنعاس أثناء تناولك اكيومج.</li></ul><p><strong>يحتوي اكيومج على الصوديوم&nbsp;</strong><br />يحتوي اكيومج على الصوديوم. يحتوي كل قرص مغطى بطبقة رقيقة من اكيومج 50 ملغم و100 ملغم من أقراص مغطاة بطبقة رقيقة على 0.468 ملغم أو 0.936 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص مغطى بطبقة رقيقة، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>تناول اكيومج تماماً كما وصفه لك مقدم الرعاية الصحية الخاص بك.</li><li>الجرعة الموصى بها هي 50 ملغم، 100 ملغم، أو 200 ملغم تؤخذ عن طريق الفم، حسب الحاجة. يجب عدم تناول أكثر من جرعة واحدة خلال 24 ساعة، ويجب عدم تناول اكيومج إلا إذا كان المريض يستطيع الانتظار لمدة 8 ساعات على الأقل بين الجرعات والقيادة أو تشغيل الآلات.</li><li>لم تظهر جرعة ثانية من لاسميديتان فعاليتها في نفس نوبة الصداع النصفي.</li><li>قد يقوم مقدم الرعاية الصحية الخاص بك بتغيير جرعتك. لا تغير جرعتك من دون استشارة مقدم الرعاية الصحية لديك أولاً.</li><li>تناول أقراص اكيومج عن طريق الفم مع الطعام أو بدونه.</li><li>ابتلع أقراص اكيومج كاملة. لا تقسم الأقراص، تسحقها، أو تمضغها.</li></ul><p dir="RTL"><strong>إذا تناولت اكيومج أكثر من اللازم</strong></p><ul dir="rtl"><li>لا تأخذ أكثر من جرعة واحدة في فترة 24 ساعة.</li><li>إذا كنت تتناول لاسميديتان 50 ملغم، 100 ملغم، أو 200 ملغم، واختفى صداعك لكنه عاد، فلا يجب أن تأخذ جرعة ثانية خلال 24 ساعة.</li><li>قد يعاني بعض الأشخاص الذين يتناولون الكثير من أقراص اكيومج، من نوبات صداع شديدة (صداع عند الإفراط في تناول الدواء). إذا تفاقمت نوبات الصداع لديك، قد يقرر مقدم الرعاية الصحية الخاص بك إيقاف العلاج باستخدام اكيومج.</li><li>يجب أن تكتب متى تعاني من الصداع ومواعيد تناول اكيومج، حتى تتمكن من التحدث إلى مقدم الرعاية الصحية الخاص بك حول كيفية عمل اكيومج معك.</li></ul><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>يمكن أن يسبب لاسميديتان آثاراً جانبية خطيرة، بما في ذلك:&nbsp;</em></strong><br /><strong>انظر &quot;ما هي أهم المعلومات التي يجب أن أعرفها عن لاسميديتان؟&quot;</strong></p><ul dir="rtl"><li>متلازمة السيروتونين. متلازمة السيروتونين هي مشكلة نادرة ولكنها خطيرة يمكن أن تحدث عند الأشخاص الذين يستخدمون لاسميديتان، خاصة إذا تم استخدام لاسميديتان مع الأدوية المضادة للاكتئاب التي تسمى مثبطات استرداد السيروتونين الانتقائية أو مثبطات استرداد السيروتونين والنورأدرينالين. اتصل بمقدم الرعاية الصحية الخاص بك على الفور إذا كنت تعاني من أي من الأعراض التالية لمتلازمة السيروتونين:<ul><li>تغيرات ذهنبة مثل رؤية أشياء غير موجودة (هلوسات)، تهيج، أو غيبوبة</li><li>سرعة نبضات القلب</li><li>تغيرات في ضغط الدم</li><li>ارتفاع درجة حرارة الجسم</li><li>عضلات مشدودة</li><li>صعوبة في المشي</li><li>غثيان، قيء، أو إسهال</li></ul></li><li>صداع عند الإفراط في تناول الدواء. قد يعاني بعض الأشخاص الذين يتناولون أدوية مثل لاسميديتان لعلاج نوبات الصداع النصفي الحادة لمدة 10 أيام أو أكثر كل شهر من نوبات صداع أسوأ (صداع الإفراط في تناول الأدوية). إذا تفاقمت نوبات الصداع لديك، قد يقرر مقدم الرعاية الصحية الخاص بك إيقاف العلاج باستخدام لاسميديتان.</li></ul><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعاً للاسميديتان ما يأتي: </strong></p><ul dir="rtl"><li>دوخة</li><li>تنميل</li><li>شعور بوخز</li><li>نعاس</li><li>شعور بالإرهاق</li></ul><p dir="RTL">أخبر مقدم الرعاية الصحية إذا كنت تعاني من أي أثر جانبي يزعجك أو لا يزول. هذه ليست كل الآثار الجانبية المحتملة للاسميديتان. لمزيد من المعلومات، اسأل مقدم الرعاية الصحية الخاص بك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي لاسميديتان نصف السكسينات.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من اكيومج 50 ملغم أقراص مغطاة بطبقة رقيقة على 57.825 ملغم لاسميديتان نصف السكسينات يكافئ 50 ملغم لاسميديتان.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من اكيومج 100 ملغم أقراص مغطاة بطبقة رقيقة على 115.65 ملغم لاسميديتان نصف السكسينات يكافئ 100 ملغم لاسميديتان.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي سيلليلوز بلوري مكروي، النشا المعدّل، كروسكارميللوز الصوديوم، كبريتات لوريل الصوديوم، سايلويد، ستيرات المغنيسيوم، أوبادري رمادي (فقط في اكيومج 50 ملغم أقراص مغطاة بطبقة رقيقة) وأوبادري بنفسجي (فقط في اكيومج 100 ملغم أقراص مغطاة بطبقة رقيقة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اكيومج 50 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاوية مغطاة بطبقة رقيقة ذات لون رمادي فاتح، محفور &ldquo;LH&rdquo; على أحد الجانبين و&quot;1&quot; على الجانب الآخر في أشرطة من الألومنيوم-الألومنيوم.</p><p dir="RTL">اكيومج 100 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاوية مغطاة بطبقة رقيقة ذات لون بنفسجي فاتح، محفور &ldquo;LH&rdquo; على أحد الجانبين و&quot;2&quot; على الجانب الآخر في أشرطة من الألومنيوم-الألومنيوم.</p><p dir="RTL">حجم العبوة: 4 و/أو 8 أقراص مغطاة بطبقة رقيقة.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق، محرر التشغيلة والشركة المصنعة للمستحضر النهائي&nbsp; &nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>&nbsp;الإمارات العربية المتحدة</li></ul><p dir="ltr">قسم اليقظة الدوائية والجهاز الطبي<br />صندوق بريد: 3581<br />هاتف: 11111008<br />pv@mohap.gov.ae : البريد الإلكتروني<br />إدارة الدواء<br />وزارة الصحة ووقاية المجتمع<br />دبي</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 07/2023؛ رقم النسخة Un1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acumig 100 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Acumig 100 mg Film-coated Tablets contains 115.65 mg lasmiditan hemi succinate equivalents to 100 mg lasmiditan.

Excipient(s) with known effect: Sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Light purple-colored oval film-coated tablets, debossed with “LH” on one side and “2” on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acumig is indicated for the acute treatment of migraine with or without aura in adults.</p><p><strong>Limitations of use</strong><br />Acumig is not indicated for the preventive treatment of migraine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose of lasmiditan is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours, and Acumig should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery [see Special warnings and precautions for use (4.4)].</p><p>A second dose of lasmiditan has not been shown to be effective for the same migraine attack.</p><p>The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.</p><p>Acumig may be taken with or without food.</p><p>Administer tablets whole; do not split, crush, or chew.</p><p><strong>Pediatric Use</strong><br />Safety and effectiveness in pediatric patients have not been established.</p><p><strong>Geriatric Use</strong><br />In controlled clinical trials, dizziness occurred more frequently in patients who were at least 65 years of age (19% for lasmiditan, 2% for placebo) compared to patients who were less than 65 years of age (14% for lasmiditan, 3% for placebo). A larger increase in systolic blood pressure also occurred in patients 65 years of age and older compared to patients who were less than 65 years of age [see Undesirable effects (4.8.)]. Clinical studies of lasmiditan did not include sufficient numbers of subjects aged 65 and over to determine whether there is a difference in efficacy in these patients compared to younger subjects. However, in clinical pharmacology studies, no clinically relevant effect on exposure to lasmiditan was observed in elderly subjects [see Pharmacological properties (5.)]. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p><strong>Hepatic Impairment</strong><br />No dosage adjustment is needed for patients with mild or moderate hepatic impairment (Child-Pugh A or B). Lasmiditan has not been studied in patients with severe hepatic impairment (Child-Pugh C) and its use in these patients is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Driving Impairment</strong><br />Lasmiditan may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of lasmiditan significantly impaired subjects&rsquo; ability to drive [see Pharmacodynamic properties (5.1)]. Additionally, more sleepiness was reported at 8 hours following a single dose of lasmiditan compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of lasmiditan. Patients who cannot follow this advice should not take lasmiditan. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by lasmiditan.</p><p><strong>Central Nervous System Depression</strong><br />Lasmiditan may cause central nervous system (CNS) depression, including dizziness and sedation [see Undesirable effects (4.8)].</p><p>Because of the potential for lasmiditan to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, lasmiditan should be used with caution if used in combination with alcohol or other CNS depressants [see Interaction with other medicinal products and other forms of interaction (4.5)]. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after lasmiditan is taken [see Special warnings and precautions for use (4.4)].</p><p><strong>Serotonin Syndrome</strong><br />In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with lasmiditan who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with lasmiditan during coadministration with serotonergic drugs [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors]. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (e.g., hyperreflexia, incoordination), and/or gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue lasmiditan if serotonin syndrome is suspected.</p><p><strong>Medication Overuse Headache</strong><br />Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.</p><p><strong>Abuse</strong><br />Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. In a human abuse potential (HAP) study in recreational poly-drug users (n=58), single oral therapeutic doses (100 and 200 mg) and a supratherapeutic dose (400 mg) of lasmiditan were compared to alprazolam (2 mg) (C-IV) and placebo.</p><p>With all doses of lasmiditan, subjects reported statistically significantly higher &ldquo;drug liking&rdquo; scores than placebo, indicating that lasmiditan has abuse potential. In comparison to alprazolam, subjects who received lasmiditan reported statistically significantly lower &ldquo;drug liking&rdquo; scores. In the HAP study, euphoric mood occurred to a similar extent with lasmiditan 200 mg, lasmiditan 400 mg, and alprazolam 2 mg (43-49%). A feeling of relaxation was noted in more subjects on alprazolam (22.6%) than with any dose of lasmiditan (7-11%).</p><p>Phase 2 and 3 studies indicate that, at therapeutic doses, lasmiditan produced adverse events of euphoria and hallucinations to a greater extent than placebo. However these events occur at a low frequency (about 1% of patients).</p><p>Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.</p><p><strong>Dependence</strong><br />Physical withdrawal was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200 mg or 400 mg.</p><p><strong>Acumig contains sodium</strong><br />Acumig contains sodium. Each film-coated tablet of Acumig 100 mg Film-coated Tablets contains 0.936 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CNS Depressants</strong><br />Concomitant administration of lasmiditan and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of lasmiditan to cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions, lasmiditan should be used with caution if used in combination with alcohol or other CNS depressants [see Special warnings and precautions for use (4.4)].</p><p><strong>Serotonergic Drugs</strong><br />Concomitant administration of lasmiditan and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John&rsquo;s Wort) that increase serotonin may increase the risk of serotonin [see Special warnings and precautions for use (4.4)]. Use lasmiditan with caution in patients taking medications that increase serotonin.</p><p><strong>Heart Rate Lowering Drugs</strong><br />lasmiditan has been associated with a lowering of heart rate [see Undesirable effects (4.8)]. In a drug interaction study, addition of a single 200 mg dose of lasmiditan to propranolol decreased heart rate by an additional 5 beats per minute compared to propranolol alone, for a mean maximum of 19 beats per minute. Use lasmiditan with caution in patients taking concomitant medications that lower heart rate if this magnitude of heart rate decrease may pose a concern.</p><p><strong>P-glycoprotein (P-gp) Transporter Substrates</strong><br />Coadministration of lasmiditan with P-gp substrates where a small change in substrate plasma concentration may lead to serious toxicities (e.g., digoxin) is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy Exposure Registry</strong><br />There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lasmiditan during pregnancy.</p><p><strong>Risk Summary</strong><br />There are no adequate data on the developmental risk associated with the use of lasmiditan in pregnant women. In animal studies, adverse effects on development (increased incidences of fetal abnormalities, increased embryofetal and offspring mortality, decreased fetal body weight) occurred at maternal exposures less than (rabbit) or greater than (rat) those observed clinically (see Data).</p><p>In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated rates of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</p><p><strong>Clinical Considerations</strong><br /><em>Disease-Associated Maternal and/or Embryo/Fetal Risk</em><br />Published data have suggested that women with migraine may be at increased risk for preeclampsia and gestational hypertension during pregnancy.</p><p><strong>Data</strong><br /><em>Animal Data</em><br />Oral administration of lasmiditan (0, 100, 175, or 250 mg/kg/day) to pregnant rats throughout organogenesis resulted in increases in skeletal variations at the mid and high doses and reduced fetal body weight at the high dose. The high dose was associated with maternal toxicity. At the no-effect dose (100 mg/kg/day) for adverse effects on embryofetal development in rats, plasma exposure (AUC) was approximately 10 times that in humans at the MRHD.</p><p>Oral administration of lasmiditan (0, 50, 75, or 115 mg/kg/day) to pregnant rabbits throughout organogenesis resulted in malformations (skeletal and visceral), increases in skeletal variations and embryofetal mortality, and decreased fetal body weight at the highest dose tested, which was associated with maternal toxicity. Plasma exposure (AUC) at the no-effect dose (75 mg/kg/day) for adverse effects on embryofetal development in rabbits was less than that in humans at the MRHD.</p><p>Oral administration of lasmiditan (0, 100, 150, or 225 mg/kg/day) to rats throughout pregnancy and lactation resulted in increases in stillbirth and neonatal mortality at the highest dose tested, which was associated with maternal toxicity and delayed parturition. Plasma exposure (AUC) at the no-effect dose (150 mg/kg/day) for adverse effects on pre-and postnatal development was approximately 16 times that in humans at the MRHD.</p><p><strong>Lactation</strong><br /><em>Risk Summary</em><br />There are no data on the presence of lasmiditan in human milk, the effects of lasmiditan on the breastfed infant, or the effects of lasmiditan on milk production. Excretion of lasmiditan and/or metabolites into milk, at levels approximately 3 times those in maternal plasma, was observed in lactating rats following oral administration of lasmiditan.</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for lasmiditan and any potential adverse effects on the breastfed infant from lasmiditan or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>lasmiditan may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of lasmiditan significantly impaired subjects&rsquo; ability to drive [see Pharmacodynamic properties (5.1)]. Additionally, more sleepiness was reported at 8 hours following a single dose of lasmiditan compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of lasmiditan. Patients who cannot follow this advice should not take lasmiditan. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by lasmiditan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are described elsewhere in the labeling [see Special warnings and precautions for use (4.4)]:</p><ul><li>Driving Impairment</li><li>Central Nervous System Depression</li><li>Serotonin Syndrome</li><li>Medication Overuse Headache</li></ul><p><strong>Clinical Trials Experience</strong><br />Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p><p>The safety of lasmiditan has been evaluated in 4,878 subjects who received at least one dose of lasmiditan. In 2 placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 3,177 patients received lasmiditan 50, 100, or 200 mg [see Pharmacodynamic properties (5.1)]. Of the lasmiditan-treated patients in these 2 studies, approximately 84% were female, 78% were White, 18% were Black, and 18% were of Hispanic or Latino ethnicity. The mean age at study entry was 42.4 years (range 18 to 81).</p><p>Long-term safety was assessed for 2,030 patients, dosing intermittently for up to 12 months in a long-term safety study. Of these, 728 patients were exposed to 100 mg or 200 mg for at least 3 months, 361 patients were exposed to these doses for at least 6 months, and 180 patients were exposed to these doses for at least 12 months, all of whom treated at least 2 migraine attacks per month on average. In that study, 14% (148 out of 1,039) in the 200 mg dose group, and 11% (112 out of 991) in the 100 mg dose group withdrew from the trial because of an adverse event. The most common adverse event resulting in discontinuation in the long-term safety study (greater than 2%) was dizziness.</p><p>Table 1 shows adverse reactions that occurred in at least 2% of patients treated with lasmiditan and more frequently than in patients who received placebo in Studies 1 and 2. The most common adverse reactions (at least 5%) were dizziness, fatigue, paresthesia, and sedation.</p><p><strong>Table 1: Adverse Reactions Occurring in &ge;2% and at a Frequency Greater than Placebo in Studies 1 and 2</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 50 mg N=654 %</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 100 mg N=1265 %</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 200 mg N=1258 %</strong></p></td><td style="vertical-align:top"><p><strong>Placebo N=1262 %</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Fatiguea</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Paresthesiab</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Sedationc</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Nausea and/or Vomiting</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Muscle Weakness</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>a Fatigue includes the adverse reaction related terms asthenia and malaise.<br />b Paresthesia includes the adverse reaction related terms paresthesia oral, hypoesthesia, and hypoesthesia oral.<br />c Sedation includes the adverse reaction related term somnolence.</p><p><em>Less Common Adverse Reactions</em><br />The following adverse reactions occurred in less than 2% of lasmiditan-treated patients but more frequently than in patients receiving placebo: vertigo, incoordination, lethargy, visual impairment, feeling abnormal, feeling hot or feeling cold, palpitations, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, muscle spasm, limb discomfort, cognitive changes, confusion, euphoric mood, chest discomfort, speech abnormalities, dyspnea, and hallucinations.</p><p><em>Hypersensitivity</em><br />Events of hypersensitivity, including angioedema, rash and photosensitivity reaction, occurred in patients treated with lasmiditan. In controlled trials, hypersensitivity was reported in 0.2% of patients treated with lasmiditan compared to no patients who received placebo. If a serious or severe hypersensitivity reaction occurs, initiate appropriate therapy and discontinue administration of lasmiditan.</p><p><em>Vital Sign Changes</em></p><ul><li>Heart Rate Decrease</li></ul><p>Lasmiditan was associated with mean decreases in heart rate of 5 to 10 beats per minute (bpm) while placebo was associated with mean decreases of 2 to 5 bpm. Consider evaluating heart rate after administration of lasmiditan in patients for whom these changes may not be tolerated, including patients taking other medications that lower heart rate [see Interaction with other medicinal products and other forms of interaction (4.5)].</p><ul><li>Blood Pressure Increase</li></ul><p>Lasmiditan may increase blood pressure following a single dose. In non-elderly healthy volunteers there was a mean increase from baseline in ambulatory systolic and diastolic blood pressure of approximately 2 to 3 mm Hg one hour after administration of 200 mg lasmiditan compared to a mean increase of up to 1 mm Hg for placebo. In healthy volunteers over 65 years of age, there was a mean increase from baseline in ambulatory systolic blood pressure of 7 mm Hg one hour after administration of 200 mg lasmiditan compared to a mean increase of 4 mm Hg for placebo. By 2 hours, there were no increases in mean blood pressure with lasmiditan compared to placebo. Lasmiditan has not been well studied in patients with ischemic heart disease. Consider evaluating blood pressure after administration of lasmiditan in patients for whom these changes may not be tolerated.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no available data.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Mechanism of Action</em></strong><br />Lasmiditan binds with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.</p><p><strong><em>Clinical Studies</em><br />Migraine</strong><br />The efficacy of lasmiditan in the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials [Study 1 (NCT02439320) and Study 2 (NCT02605174)]. These studies enrolled patients with a history of migraine with and without aura according to the International Classification of Headache Disorders (ICHD-II) diagnostic criteria. Patients were predominantly female (84%), and White (78%), with a mean age of 42 years (range 18-81). Twenty-two percent of patients were taking preventive medication for migraine at baseline. Study 1 randomized patients to lasmiditan 100 mg (n=744), or 200 mg (n=745) or placebo (n=742) and Study 2 randomized patients to lasmiditan 50 mg (n=750), 100 mg (n=754), or 200 mg (n=750) or placebo (n=751). Patients were allowed to take a rescue medication 2 hours after taking study drug; however, opioids, barbiturates, triptans, and ergots were not allowed within 24 hours of study drug administration.</p><p>The primary efficacy analyses were conducted in patients that treated a migraine with moderate to severe pain within 4 hours of the onset of the attack. The efficacy of lasmiditan was established by an effect on pain freedom at 2 hours and Most Bothersome Symptom (MBS) freedom at 2 hours compared to placebo for Studies 1 and 2. Pain freedom was defined as a reduction of moderate or severe headache pain to no pain, and MBS freedom was defined as the absence of the self-identified MBS (photophobia, phonophobia, or nausea). Among patients who selected an MBS, the most commonly selected MBS was photophobia (54%), followed by nausea (24%), and phonophobia (22%).</p><p>In both studies, the percentage of patients achieving pain freedom and MBS freedom 2 hours after treatment was significantly greater among patients receiving lasmiditan at all doses compared to those receiving placebo (see Table 2).</p><p><strong>&nbsp;Table 2: Migraine Efficacy Endpoints after Treatment for Studies 1 and 2</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Study 1</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lasmiditan 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 200 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 50 mg</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 200 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Pain Free at 2 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>498</p></td><td style="vertical-align:top"><p>503</p></td><td style="vertical-align:top"><p>515</p></td><td style="vertical-align:top"><p>544</p></td><td style="vertical-align:top"><p>523</p></td><td style="vertical-align:top"><p>521</p></td><td style="vertical-align:top"><p>534</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>28.3</p></td><td style="vertical-align:top"><p>31.8</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>28.3</p></td><td style="vertical-align:top"><p>31.4</p></td><td style="vertical-align:top"><p>38.8</p></td><td style="vertical-align:top"><p>21.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>16.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>10.4</p></td><td style="vertical-align:top"><p>17.8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>p-value </em></p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>MBS Free at 2 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>464</p></td><td style="vertical-align:top"><p>467</p></td><td style="vertical-align:top"><p>480</p></td><td style="vertical-align:top"><p>502</p></td><td style="vertical-align:top"><p>491</p></td><td style="vertical-align:top"><p>478</p></td><td style="vertical-align:top"><p>509</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>41.2</p></td><td style="vertical-align:top"><p>40.7</p></td><td style="vertical-align:top"><p>29.6</p></td><td style="vertical-align:top"><p>40.8</p></td><td style="vertical-align:top"><p>44.0</p></td><td style="vertical-align:top"><p>48.7</p></td><td style="vertical-align:top"><p>33.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>11.1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>p-value </em></p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Pain relief at 2 hours, defined as a reduction in migraine pain from moderate or severe to mild or none, was also evaluated (see Table 3).</p><p><strong>Table 3: Additional Migraine Efficacy Endpoint after Treatment for Studies 1 and 2</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Study 1</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lasmiditan 100 mg </strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 200 mg </strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 50 mg </strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 100 mg </strong></p></td><td style="vertical-align:top"><p><strong>Lasmiditan 200 mg </strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Pain Relief at 2 hours<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>498</p></td><td style="vertical-align:top"><p>503</p></td><td style="vertical-align:top"><p>515</p></td><td style="vertical-align:top"><p>544</p></td><td style="vertical-align:top"><p>523</p></td><td style="vertical-align:top"><p>521</p></td><td style="vertical-align:top"><p>534</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>54.0</p></td><td style="vertical-align:top"><p>55.3</p></td><td style="vertical-align:top"><p>40.0</p></td><td style="vertical-align:top"><p>55.9</p></td><td style="vertical-align:top"><p>61.4</p></td><td style="vertical-align:top"><p>61.0</p></td><td style="vertical-align:top"><p>45.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>14.0</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>16.3</p></td><td style="vertical-align:top"><p>15.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a The analysis of pain relief was descriptive and was not controlled for Type I error.</p><p><strong>&nbsp;</strong>Figure 1 presents the percentage of patients achieving migraine pain freedom within 2 hours following treatment in Studies 1 and 2.</p><p><strong>Figure 1: Percentage of Patients Achieving Migraine Pain Freedom within 2 Hours in Pooled Studies 1 and 2</strong></p><p><img src="data:image/png;base64,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" alt="" width="636" height="449" vspace="0" hspace="0" border="0" style="width:636px;height:449px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Figure 2 presents the percentage of patients achieving MBS freedom within 2 hours in Studies 1 and 2.</p><p><strong>Figure 2: Percentage of Patients Achieving MBS Freedom within 2 Hours in Pooled Studies 1 and 2 </strong></p><p><img src="data:image/png;base64,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" alt="" width="636" height="451" vspace="0" hspace="0" border="0" style="width:636px;height:451px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>a The 50 mg arm was only included in Study 2.</p><p><strong>Effects on Driving</strong><br />Driving performance was assessed at 90 minutes after administration of lasmiditan 50 mg, 100 mg, 200 mg, alprazolam 1 mg, and placebo in a randomized, double-blind, placebo-and active-controlled, five-period crossover study in 90 healthy volunteers (mean age 34.9 years) using a computer-based driving simulation. Driving performance was evaluated using a validated threshold established in a population with blood alcohol concentration of 0.05%. The primary outcome measure was the difference from placebo in the Standard Deviation of Lateral Position (SDLP), a measure of driving performance. A dose-dependent impairment of computer-based simulated driving performance was seen with all doses of lasmiditan at 90 minutes after administration.</p><p>Driving performance was also assessed at 8, 12, and 24 hours after administration of lasmiditan 100 mg or 200 mg, in a separate randomized, double-blind, placebo-and active-controlled, four-period crossover study in 67 healthy volunteers (mean age 32.8 years) evaluating computer-based simulated driving performance using SDLP as the primary endpoint. Diphenhydramine 50 mg was used as a positive control. The mean SDLP did not reach the threshold for driving impairment at 8 hours or later after administration of lasmiditan 100 or 200 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong><br />Following oral administration, lasmiditan is rapidly absorbed with a median t<sub>max</sub> of 1.8 hours. In patients with migraine, the absorption or pharmacokinetics of lasmiditan was not different during a migraine attack versus during the interictal period.</p><p><strong>Effect of Food</strong><br />Coadministration of lasmiditan with a high-fat meal increased the mean lasmiditan C<sub>max</sub> and AUC values by 22% and 19%, respectively, and delayed the median t<sub>max</sub> by 1 hour. This difference in exposure is not expected to be clinically significant [see Posology and method of administration (4.2)]. Lasmiditan was administered without regard to food in clinical efficacy studies.</p><p><strong><em>Distribution</em></strong><br />The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/ml.</p><p><strong><em>Elimination</em></strong><br />Lasmiditan was eliminated with a geometric mean t<sub>&frac12;</sub> value of approximately 5.7 hours. No accumulation of lasmiditan was observed with daily dosing. Lasmiditan is primarily eliminated via metabolism, with ketone reduction representing the major pathway. Renal excretion is a minor route of lasmiditan clearance.</p><p><strong>Metabolism</strong><br />Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-CYP enzymes. The following enzymes are not involved in metabolism of lasmiditan: MAO-A, MAO-B, flavin monooxygenase 3, CYP450 reductase, xanthine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, and aldo-keto reductases. Lasmiditan is also metabolized to M7 (oxidation on piperidine ring) and M18 (combination of M7 and M8 pathways). These metabolites are considered pharmacologically inactive.</p><p><strong>Excretion</strong><br />Recovery of unchanged lasmiditan in urine was low and accounted for approximately 3% of the dose. Metabolite S-M8 represented approximately 66% of the dose in urine, with the majority of recovery within 48 hours postdose.</p><p><strong><em>Specific Populations</em><br />Age, Sex, Race/Ethnicity, and Body Weight</strong><br />Based on a population pharmacokinetic (PK) analysis, age, sex, race/ethnicity, and body weight did not have a significant effect on the PK (C<sub>max</sub> and AUC) of lasmiditan. Therefore, no dose adjustments are warranted based on age, sex, race/ethnicity, or body weight.</p><p><strong>Geriatric Use</strong><br />In a clinical pharmacology study, administration of lasmiditan to subjects 65 years of age or older demonstrated 26% greater exposure in AUC<sub>(0-&infin;)</sub> and 21% higher C<sub>max</sub>, compared to subjects 45 years of age or less. This difference in exposure is not expected to be clinically significant.</p><p><strong>Renal Impairment</strong><br />In a clinical pharmacology study, administration of lasmiditan to subjects with severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) demonstrated 18% greater exposure in AUC<sub>(0-&infin;)</sub> and 13% higher C<sub>max</sub>, compared to subjects with normal renal function. No dose adjustment is required based on renal function.</p><p><strong>Hepatic Impairment</strong><br />In a clinical pharmacology study, subjects with mild and moderate hepatic impairment (Child-Pugh Class A and B, respectively) demonstrated 11% and 35%, respectively, greater exposure [AUC<sub>(0-&infin;)</sub>] to lasmiditan, compared to subjects with normal hepatic function. The C<sub>max</sub> were higher by 19% and 33%, respectively, for subjects with mild and moderate hepatic impairment. This difference in exposure is not expected to be clinically significant. The use of lasmiditan has not been studied in subjects with severe hepatic impairment.</p><p><strong><em>Drug Interaction Studies</em><br />Potential for Lasmiditan to Affect Other Drugs</strong><br /><em>Drug Metabolizing Enzymes</em><br />Lasmiditan is an <em>in-vitro</em> inhibitor of CYP2D6 but did not significantly inhibit the activity of other CYP450 enzymes. Modeling and simulation of the impact of lasmiditan on the exposure of dextromethorphan, a recognized sensitive CYP2D6 substrate, indicate that lasmiditan is unlikely to exert clinically significant inhibition of CYP2D6. Lasmiditan, M7, S-M8, and [S,R]-M18 are not reversible or time-dependent inhibitors of monoamine oxidase A (MAO-A).</p><p>Daily dosing of lasmiditan did not alter the PK of midazolam, caffeine, or tolbutamide, which are substrates of CYP3A, CYP1A2, and CYP2C9, respectively. Coadministration of lasmiditan with sumatriptan, propranolol, or topiramate resulted in no clinically meaningful changes in exposure of these medicinal products.</p><p><em>Drug Transporters</em><br />In a drug interaction study in healthy volunteers, co-administration of 200 mg lasmiditan with dabigatran (P-gp substrate) increased the systemic exposures, AUC and C<sub>max</sub>, of dabigatran by 25% and 22%, respectively [see Interaction with other medicinal products and other forms of interaction (4.5)]. Co-administration of 200 mg lasmiditan with rosuvastatin (BCRP substrate) did not affect exposures of rosuvastatin.</p><p>Lasmiditan inhibits OCT1 <em>in-vitro</em>. However, in a drug-drug interaction study with lasmiditan and sumatriptan (OCT1 substrate), no change in sumatriptan PK was observed. Lasmiditan inhibits renal efflux transporters, MATE1 and MATE2- K, <em>in-vitro</em>.</p><p><strong>Potential for Other Drugs to Affect Lasmiditan</strong><br /><em>Drug Metabolizing Enzymes</em><br />Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-CYP enzymes. Therefore, it is unlikely that CYP inhibitors or inducers will affect lasmiditan pharmacokinetics. Clinical studies of lasmiditan with sumatriptan, propranolol, or topiramate did not show any significant drug interaction potential.</p><p><em>Drug Transporters</em><br />Lasmiditan is a substrate for P-gp <em>in-vitro</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong><br /><em>Carcinogenesis</em><br />No drug-related tumors were observed following oral administration of lasmiditan to TgRasH2 mice at doses of up to 150 (males) or 250 (females) mg/kg/day for 26 weeks or to rats at doses of up to 75 mg/kg/day for 2 years. Plasma exposures (AUC) at the highest dose tested in rats were approximately 15 times that in humans at the maximum recommended human dose (MRHD) of 200 mg/day.</p><p><em>Mutagenesis</em><br />Lasmiditan was negative in <em>in vitro</em> (bacterial reverse mutation, chromosomal aberration in mammalian cells) and <em>in vivo</em> (mouse bone marrow micronucleus) assays.</p><p><em>Impairment of Fertility</em><br />Oral administration of lasmiditan to male (0, 100, 175, or 200 mg/kg/day) or female (0, 100, 150, or 200 mg/kg/day) rats prior to and during mating and continuing in females to Gestation Day 7 resulted in no adverse effects on fertility or reproductive performance. Plasma exposures (AUC) at the highest dose tested (200 mg/kg/day) were approximately 26 times that in humans at the MRHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp; Pregelatinized starch</p><p>-&nbsp;&nbsp;&nbsp; Croscarmellose sodium</p><p>-&nbsp;&nbsp;&nbsp; Sodium lauryl sulfate</p><p>-&nbsp;&nbsp;&nbsp; Syloid</p><p>-&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p>-&nbsp;&nbsp;&nbsp; Opadry purple</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-aluminum blisters.</p><p>Pack sizes: 4 and/or 8 Film-coated Tablets.</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>